Gemini Therapeutics, Inc. /De (GMTX)

Trade GMTX now with
10/5/2021 7:07:08 AM Gemini Therapeutics Announces Corporate Restructuring; To Reduce Employee Headcount By 20%
9/10/2021 8:35:15 AM Gemini Reports Presentation Of Preclinical Data At 13th International Conference On Complement Therapeutics
8/12/2021 7:19:41 AM Gemini Therapeutics Q2 Net Loss $16.4 Mln Or $0.38/Shr Vs Loss Of $6.8 Mln Or $0.44/Shr Last Year
6/22/2021 5:55:26 PM Gemini Therapeutics Falls 35%
5/13/2021 7:19:20 AM Gemini Therapeutics Q1 Net Loss $19.0 Mln Or $0.59/Shr Vs Loss Of $9.7 Mln Or $0.67/Shr Last Year
5/13/2021 7:15:26 AM Gemini Therapeutics Completes Enrollment In Phase 2a Study Of GEM103 As An Add-On To Anti-VEGF Therapy
5/3/2021 7:10:20 AM Gemini Therapeutics Appoints Georges Gemayel As Chair Of Board Of Directors
4/13/2021 8:12:33 AM Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
4/12/2021 8:06:55 AM Gemini Therapeutics Appoints Samuel Barone As Chief Medical Officer
2/10/2021 7:35:33 AM Gemini Says Completes Phase 2a Trial Enrollment For GEM103 In Dry AMD Patients With High-Risk Genetic Variants